Zacks Research Analysts Lower Earnings Estimates for Perrigo

Perrigo Company plc (NYSE:PRGO) – Investment analysts at Zacks Research lowered their Q1 2026 EPS estimates for shares of Perrigo in a research note issued on Thursday, March 19th. Zacks Research analyst Team now expects that the company will post earnings of $0.57 per share for the quarter, down from their prior forecast of $0.78. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.55 EPS, Q4 2026 earnings at $0.61 EPS, FY2026 earnings at $2.18 EPS, Q1 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.63 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $2.53 EPS.

Perrigo (NYSE:PRGO) last announced its earnings results on Thursday, February 26th. The company reported $0.77 EPS for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.Perrigo’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.93 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

A number of other research firms have also recently weighed in on PRGO. Canaccord Genuity Group lowered their price objective on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Argus upgraded shares of Perrigo to a “hold” rating in a research report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Perrigo currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Stock Performance

Shares of PRGO opened at $9.25 on Monday. The business has a 50-day simple moving average of $13.29 and a two-hundred day simple moving average of $16.01. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. Perrigo has a 52 week low of $9.23 and a 52 week high of $28.43. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -0.90, a PEG ratio of 1.09 and a beta of 0.41.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be paid a dividend of $0.29 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a yield of 12.5%. Perrigo’s dividend payout ratio is presently -11.28%.

Institutional Trading of Perrigo

Hedge funds have recently modified their holdings of the company. Amundi raised its stake in Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after buying an additional 647,982 shares during the last quarter. United Services Automobile Association bought a new stake in shares of Perrigo in the 1st quarter worth about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Perrigo by 6.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after buying an additional 32,151 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Perrigo

Here are the key news stories impacting Perrigo this week:

• Negative Sentiment: Zacks slashed Q1–Q4 2026 and several 2027 quarterly estimates, lowering FY2026 EPS to $2.18 (from $3.00) and FY2027 to $2.53 (from $3.18) — signaling weaker near‑term profit expectations and prompting a “Hold” stance. MarketBeat: Zacks Lowers Perrigo Estimates
• Negative Sentiment: Zacks specifically cut quarterly EPS forecasts across multiple quarters (e.g., Q1 2026 to $0.57 from $0.78; Q2 2026 to $0.45 from $0.63; Q3/Q4 2026 and several 2027 quarters also reduced), increasing the risk that Perrigo will need to re‑accelerate margins or growth to meet consensus. MarketBeat: Zacks Lowers Quarterly Estimates
• Negative Sentiment: Separate coverage summarizing Zacks’ Q2 estimate and commentary reiterated the weaker consensus outlook for near‑term EPS — reinforcing the market’s negative reaction to the downgraded profitability trajectory. Zacks Research Estimates Perrigo’s Q2 Earnings

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.